News
-
-
-
COMMUNIQUÉ DE PRESSE
LQR House Inc. Announces Share Acquisition by MeiFang Group at $1.58/Share and Agreement for Share Acquisition by Winz Technology Co. at $2.85/Share, Along With Highly Qualified Board Nominations
LQR House Inc. partners with MeiFang Group & Winz Technology Co., appoints Yilin Lu and Hong Chun Yeung to Board of Directors, strengthening market position and growth strategies -
-
COMMUNIQUÉ DE PRESSE
Trans Canada Gold Provides Operational Results Highlighted by Multilateral Drilling Success, Increased Crude Oil Production, and Higher Production Revenue
Trans Canada Gold Corp. reports robust oil production and significant revenue growth in fiscal year 2024. Strategic partnerships and operational milestones drive success. Company plans additional multilateral drilling in 2025 -
COMMUNIQUÉ DE PRESSE
Abasca Resources Announces Multiple Graphite Intersections at Its Loki Flake Graphite Zone Including 52 m at 7.18 % Cg
Abasca Resources Inc. reports positive assay results from the 2024 summer exploration program at Key Lake South Project, focusing on graphite mineralization in the Loki Flake Graphite Zone -
COMMUNIQUÉ DE PRESSE
Sokoman Provides Project Update, Moosehead Gold Project, Central Newfoundland
Sokoman Minerals Corp. initiates 1,500 m drilling program at the Western Trend gold zone to test high-grade mineralization. Channel sample results confirm East-West vein system. Metallurgical testing ongoing -
-
COMMUNIQUÉ DE PRESSE
PHAXIAM présente une stratégie de développement ambitieuse pour tirer parti de l'évolution rapide du marché de la phagothérapie
PHAXIAM présente une stratégie de développement ambitieuse pour tirer parti de l'évolution rapide du marché de la phagothérapie. Tenue d’un webinaire pour présenter la stratégie ambitieuse de la Société PHAXIAM Therapeutics. Objectif : rentabilité opérationnelle et cash-flow positif en 2027 -
COMMUNIQUÉ DE PRESSE
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area. Webinar discussing PTMP and IPT models with revenue projections and positive outlook for achieving profitability by 2027
